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Abstract
Background: Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial
evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for
newly diagnosed glioblastoma.
Methods: After surgery and chemoradiotherapy, patients were randomized (2:1) to receive temozolomide plus
DCVax-L (n = 232) or temozolomide and placebo (n = 99). Following recurrence, all patients were allowed to receive
DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); the secondary endpoint was
overall survival (OS).
Results: For the intent-to-treat (ITT) population (n = 331), median OS (mOS) was 23.1 months from surgery. Because
of the cross-over trial design, nearly 90% of the ITT population received DCVax-L. For patients with methylated
MGMT (n = 131), mOS was 34.7 months from surgery, with a 3-year survival of 46.4%. As of this analysis, 223 patients
are ≥ 30 months past their surgery date; 67 of these (30.0%) have lived ≥ 30 months and have a Kaplan-Meier (KM)derived mOS of 46.5 months. 182 patients are ≥ 36 months past surgery; 44 of these (24.2%) have lived ≥ 36 months
and have a KM-derived mOS of 88.2 months. A population of extended survivors (n = 100) with mOS of 40.5 months,
not explained by known prognostic factors, will be analyzed further. Only 2.1% of ITT patients (n = 7) had a grade 3
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or 4 adverse event that was deemed at least possibly related to the vaccine. Overall adverse events with DCVax were
comparable to standard therapy alone.
Conclusions: Addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend
survival.
Trial registration Funded by Northwest Biotherapeutics; Clinicaltrials.gov number: NCT00045968; https://clinicaltrials.
gov/ct2/show/NCT00045968?term=NCT00045968&rank=1; initially registered 19 September 2002
Keywords: Glioblastoma, Immunotherapy, Dendritic cell, Vaccine

Background
Glioblastoma is the most aggressive primary malignant brain tumor in adults [1]. Standard of care (SOC)
consists of surgical resection followed by 6 weeks of
daily radiotherapy with concurrent temozolomide, then
monthly temozolomide [2]. Median overall survival
(mOS) under this SOC is only 15–17 months [2, 3],
and ≤ 5% of patients are alive at 5 years [3]. Loco-regional
therapy with alternating electric fields has recently shown
an increase in median PFS (mPFS) to 6.7 months and
mOS to 20.9 months from randomization, respectively
[4]. However, there has been no material advance in survival with systemic therapies since the addition of temozolomide 12 years ago, despite investigations with many
diverse agents [2, 5–10].
Immunotherapy is an appealing strategy because of the
potential ability for immune cells to traffic to and destroy
infiltrating tumor cells. Dendritic cells (DCs) are central
to the immune system as key regulators of immune tolerance and immunity [11]. For more than a decade, our
group and others have been testing active vaccination
strategies, such as DCs pulsed with tumor lysates or synthetic peptides to induce antitumor immunity in glioblastoma patients [12, 13]. We have previously demonstrated
the effectiveness of DC vaccination in pre-clinical models
[14–16], and early stage clinical trials have shown substantial promise [17–19].
In this report, we describe the blinded interim data of
the overall ITT patient population enrolled in a Phase 3
randomized, double-blinded, placebo-controlled clinical trial of an autologous tumor lysate-pulsed dendritic
cell vaccine (DCVax®-L) for newly diagnosed glioblastoma. To date, we have not yet reached sufficient
events (i.e., deaths) in this trial to justify unblinding.
Nevertheless, since the vast majority (86.4%) of the ITT
population received the experimental DC treatment at
some point during the trial because of the cross-over
study design, analysis of the interim data may provide
early insight into the impact of DCVax-L on overall
survival. A final analysis of the data obtained in this
trial following unblinding will occur once sufficient
events of disease progression or death have occurred

to fully elucidate patient survival data in the tail of the
survival curve.

Methods
Study patients

Patients were eligible for this study if they were
18–70 years of age and had newly diagnosed glioblastoma, as determined through central pathology review.
Other eligibility criteria included Karnofsky Performance Score (KPS) of ≥ 70 [20], adequate bone marrow,
liver, and renal function, life expectancy of ≥ 8 weeks,
no other prior malignancy within the last 5 years, no
active viral infections, and sufficient resected tumor
material to produce the autologous vaccine. Patients
were excluded if they already had apparent early disease progression/recurrence or pseudo-progression at
the baseline visit, similar to the inclusion/exclusion criteria of other recent trials in glioblastoma [4, 21].
Study design and treatments

We conducted this study at over 80 sites in 4 countries:
the US, Canada, Germany, and the UK. Patient recruitment was initiated in 2007, and was paused from 2009
to 2011 for economic reasons. The midpoint of enrollment was reached in May of 2014, and the final patient
was enrolled in November of 2015. The protocol was
approved by the required independent ethics committees and institutional review boards. Written consent was
obtained from all patients participating in the trial.
All patients underwent surgical resection and 6 weeks
of chemoradiotherapy per SOC, prior to enrollment and
randomization in the study.
Randomization was performed centrally and was stratified by clinical site and MGMT (O6-methylguanine-DNA
methyltransferase) gene promoter methylation status,
which was determined by a central laboratory. Patients
were randomized 2:1 to SOC plus autologous DC vaccine (DCVax-L; n = 232) or SOC plus placebo (n = 99).
PBMCs were used as placebo control as these cells are
visually indistinguishable from DC and are considered immunologically inactive. Patients in both arms
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continued to receive monthly adjuvant temozolomide
(150–200 mg/m2/day × 5 days every 28 days), interspersed with the DC vaccine or placebo treatments
administered on Days 0, 10 and 20, then Months 2, 4 and
8, and thereafter at 6-month intervals starting at month
12. Each DCVax-L treatment involved a dose of 2.5 million autologous tumor lysate-pulsed DCs administered
intradermally in the upper arm, alternating arms between
injection visits.
All patients were allowed to receive DCVax-L following
tumor progression/recurrence, as well as other approved
treatments per local practice. All parties (investigators,
patients and sponsor) remained blinded as to which
treatment each patient had received prior to crossover.
All patients who chose this option were given the active
treatment on a re-start schedule with immunizations at
Days 0, 10 and 20, and then months 2, 4 and 8, and every
6 months thereafter beginning with month 12, with Day 0
being the day of the first vaccination post progression. To
date, DCVax-L has been shipped for 286 patients (86.4%)
in the trial.
Both the study treatment (DCVax-L) and placebo
(PBMC) were prepared by Cognate BioServices, Inc. for
all patients in the US and Canada, and by Cognate and
the Fraunhofer Institute for Cell Therapy together for
patients in Europe, during the chemoradiotherapy period
before the baseline visit. The production of DCVaxL involved processing the resected tumor tissue into a
lysate, and then collection, purification, differentiation,
activation and loading of the autologous DCs. In general,
approximately 2 g of tumor tissue was needed to produce
the full ten doses for the 36-month treatment and followup schedule. The vaccine was aliquoted in individual
doses and cryopreserved at < 150 °C [22]. The doses were
stored centrally, and shipped individually to the clinical
trial sites.
Assessments

Baseline assessments included physical examination, neurological examination, vitals, KPS, MRI of brain with and
without contrast, hematology (CBC with differential, platelets), and serum chemistries (calcium, magnesium, SGOT,
SGPT, alkaline phosphatase, LDH, total bilirubin, BUN,
creatinine, electrolytes, glucose). Blood was collected for
serum markers of autoimmune disease (anti-DNA) and
immune monitoring, at the baseline visit and at treatment
visits throughout the trial. MRI brain scans were performed
every 2 months, per SOC, after the baseline MRI until radiological tumor progression. All MRI scans were evaluated
centrally by 2 blinded independent radiologists, with adjudication by a third such radiologist if needed.
Adverse events were recorded prospectively according
to the National Cancer Institute’s Common Terminology
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Criteria (version 3.0 NCI CTC), until 2 months after the
last study treatment. Patients are followed for OS until
death.
Statistical analyses

The study’s primary endpoint is PFS, and the secondary
endpoint is OS. PFS has not yet been evaluated for this
publication and will be the subject of later analyses to
allow for central, multi-factorial assessment by an expert
panel, using criteria currently emerging as appropriate
for immune therapy in this patient population where progression can be complex to determine and pseudo-progression is a known confounding phenomenon. Analysis
of the blinded interim data on OS of the ITT population
(using SAS version 9.4) was performed 34 months after
the midpoint of patient enrollment, and 16 months after
the last patient was enrolled and randomized.
General descriptive statistics include the number of
observed values, mean, standard deviation, median, and
range values for continuous measures. For categorical
variables, the number and percentage of subjects with
a specific level of the variable are reported. For survival
analyses, Kaplan–Meier (KM) curves were generated,
yielding estimates of median survival times, along with
the two-sided confidence intervals (95% CIs) and estimates of survival at specific time points.

Results
Study patients

From July 2007 to November 2015, 331 patients were
recruited in the trial, comprising the intent-to-treat
(ITT) population. A flow diagram depicting the flow of
patients through the screening and enrollment process is
provided in Fig. 1. The median time from surgery to randomization was 3.1 months.
The ITT population (n = 331) (Table 1) is similar to
other recent glioblastoma trials [4, 21, 24], with 61% males
(n = 202) and 39% females (n = 129), with 75.2% of the
patients ≥ 50 years of age (range 19–73 years), and median
KPS of 90. 63.1% of patients (n = 209) had gross total
resection and 36.9% (n = 122) did not. The MGMT gene
promoter was methylated in 39.6% of patients (n = 131)
and unmethylated in 48.9% (n = 162), with information not
available for 11.5% (n = 38; the missing data relates to the
early patients enrolled a decade ago). Absolute lymphocyte
count (ALC) was > 800 cells/mm3 in 48.6% of the patients
(n = 161) and was < 800 cells/mm3 in 51.4% of patients
(n = 170), a characteristic that has been associated with
poor prognosis after radiation [23]. Patients with radiographic evidence of disease progression at baseline were
excluded, as they have also been excluded in other recent
trials for newly diagnosed glioblastoma [4, 21, 24].

Liau et al. J Transl Med (2018) 16:142

Page 4 of 9

Table 1 Baseline demographic and clinical characteristics
Variable

n = 331 (100%)

Age (year)
Mean (SD)

55.33 (10.01)

Median (range)

56 (19, 73)

Sex, n (%)
Female

129 (39.0)

Male

202 (61.0)

Race, n (%)
American Indian or Alaska Native

1 (0.3)

Asian

2 (0.6)

Black or African American
Hispanic or Latino
White
Not availablea

7 (2.1)
16 (4.8)
294 (88.8)
11 (3.3)

KPS at baseline, n (%)

Fig. 1 Recruitment, inclusion, and randomization of patients in the
study. (1) Patients are screened prior to surgery, so glioblastoma
(GBM) determination is made from pathological diagnosis
after surgery. (2) Insufficient tumor lysate generated to meet
threshold. (3) Progressive disease or pseudo-progression (which
are indistinguishable at this point) based on central review of MRI
imaging at baseline post-chemoradiation. (4) Patients who consented
to tumor donation but then declined participation in trial prior to
leukapheresis. (5) Includes deviations from standard chemoradiation
protocol, history of prior malignancy, inadequate renal or bone
marrow function, etc. (6) Includes drug product failure or insufficient
drug or placebo manufactured to meet release criteria. (7) Includes
clinical deterioration, declining Karnofsky performance status, or
patient deaths. (8) Includes biopsy only, surgery canceled, or tumor
tissue not processed after surgery

< 90

97 (29.3)

≥ 90

234 (70.7)

Methylated

131 (39.6)

Not methylated

162 (48.9)

MGMT classification, n (%)

Not available

38 (11.5)

Lymphocyte group, n (%)
High

161 (48.6)

Low

170 (51.4)

Surgical status, n (%)

a

Partial resection

122 (36.9)

Complete resection

209 (63.1)

Race is in some cases not collected due to institutional policy

Long tail among ITT population

Since other treatments were allowed following disease
progression, we assessed their usage in this trial. While
on study, three patients (1%) had another resection, 103
patients (31%) received bevacizumab, 53 patients (16%)
received CCNU and 6 patients (1.8%) were treated with
tumor treating fields. In multiple reported studies, neither bevacizumab nor CCNU have been shown to extend
survival [9, 25].

With immune-based therapies, a key focus is on the tail
of the survival curve [26]. Among the ITT patients with
a surgery date ≥ 30 months prior to the data collection (n
= 223), 30% (n = 67) have lived ≥ 30 months, and their
KM-derived mOS estimate is 46.5 months. Among the
ITT patients with a surgery date ≥ 36 months prior to
the data collection (n = 182), 24.2% (n = 44) have lived
≥ 36 months and their KM-derived mOS estimate is
88.2 months.

Treatment outcomes
ITT population

MGMT status and extent of resection

At the time of this analysis, 108 the 331 patients (32.6%)
were still alive. The mOS of the overall ITT population
(n = 331) was 23.1 months from the time of surgery (95%
CI 21.2–25.4), with 2 and 3-year survival rates of 46.2
and 25.4%, respectively (see Fig. 2a and Table 2). Analysis of patient survival relative to year of enrollment did
not reveal a trend over time, nor meaningful differences
between years.

In patients with methylated MGMT (n = 131), mOS was
34.7 months from surgery (95% CI 27.0–40.7), with 2 and
3-year survival rates of 66.7% and 46.4%, respectively. In
patients with unmethylated MGMT (n = 162), mOS was
19.8 months from surgery (95% CI 17.9–21.7), with 2 and
3-year survival rates of 32.1%, and 11.0%, respectively
(Fig. 2b and Table 2).
For patients with gross total surgical resection
(n = 209), mOS was 25.4 months from surgery (95% CI
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Fig. 2 Overall survival curves for patients in the intent-to-treat population. Overall survival analyses of time from date of surgery until death or
last follow-up according to the Kaplan–Meier method for all patients in the intent-to-treat (ITT) population (a), and the ITT population stratified by
MGMT gene promoter methylation status (b). Censored patients are annotated by a small vertical line

21.8–28.2), with 2 and 3-year survival rates of 51.2%, and
29.9%, respectively. For patients with only partial surgical
resection (n = 122), mOS from surgery was 21.1 months
(95% CI 19.1–23.1), with 2 and 3-year survival rates of
37.7%, and 18.0%, respectively (Table 2).

In patients with both MGMT methylation and gross
total resection (n = 83), the mOS was 36.5 months (95%
CI 31.5–46.5)—1.8 months longer than the mOS of
patients with MGMT methylation and only partial resection (n = 48). In patients with unmethylated MGMT,

Liau et al. J Transl Med (2018) 16:142
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Table 2 Study endpoints according to molecular genetic and clinical prognostic subgroups
Population

n

Median OS
Survival at 1 yearb
since surgery (months)a

Survival at 2 yearsb

Survival at 3 yearsb

Overall

331

23.1
(21.2, 25.4)

89.3%
(85.4, 92.2)

46.2%
(40.4, 51.8)

25.4%
(19.9, 31.3)

MGMT methylated

131

34.7
(27.0, 40.7)

94.5%
(88.8, 97.3)

66.7%
(57.5, 74.4)

46.4%
(35.8, 56.3)

MGMT un-methylated

162

19.8
(17.9, 21.7)

86.4%
(80.0, 90.8)

32.1%
(24.5, 9.9)

11.0%
(5.7, 18.2)

Gross total resection

209

25.4
(21.8, 28.2)

91.8%
(87.1, 94.8)

51.2%
(43.9, 58.1)

29.9%
(22.6, 37.5)

Partial resection

122

21.1
(19.1, 23.1)

85.0%
(77.2, 90.2)

37.7%
(28.6, 46.7)

18.0%
(10.5, 27.1)

KPS at baseline ≥ 90

234

23.7
(21.8, 26.7)

94.0%
(90.0, 96.4)

49.2%
(42.3, 55.8)

26.6%
(19.9, 33.8)

KPS at baseline < 90

97

19.8
(16.6, 23.9)

77.8%
(68.0, 84.9)

38.8%
(28.5, 49.0)

22.1%
(13.4, 32.2)

ALC > 800

161

23.6
(21.7, 28.2)

89.9%
(84.0, 93.7)

49.5%
(41.1, 57.4)

28.7%
(20.6, 37.3)

ALC ≤ 800

170

21.6
(19.9, 25.2)

88.7%
(82.8, 92.6)

43.3%
(35.4, 50.9)

22.2%
(15.0, 30.3)

Age < 50 years

82

26.2
(21.1, 31.5)

92.5%
(84.2, 96.6)

51.7%
(39.9, 62.3)

28.0%
(16.4, 40.8)

Age ≥ 50 years

249

22.4
(20.4, 24.1)

88.2%
(83.5, 91.7)

44.4%
(37.7, 50.8)

24.6%
(18.5, 31.2)

a

Median overall survival (OS) in months of intent-to-treat (ITT) population, followed by 95% confidence interval in parentheses

b

Annual rates of percentage surviving in ITT population, followed by 95% confidence interval in parentheses

there was no statistically significant survival advantage with gross total resection compared to only partial
resection.
Unknown factors: sub‑group with extended survival

Approximately 30% of the ITT population (n = 100)
showed particularly extended survival, with a KM
derived mOS estimate of 40.5 months. This is not fully
explained by known prognostic factors, as only some of
these patients had positive prognostic factors: only 29%
were younger than 50 years of age, 65.9% had methylated
MGMT, 71% had a complete resection, and only 8% of
these patients had all three positive prognostic factors.
These patients will be the subject of extensive further
analyses and research.
Safety and toxicity

Safety and toxicity data were assessed on a blinded basis
for all 331 ITT patients. Following SOC chemoradiotherapy, and before any DCVax-L treatment, lymphopenia was the most common adverse event, occurring in
approximately 170 patients (51%) [23].
The DCVax-L treatment was well tolerated, with only
7 ITT patients (2.1%) experiencing serious (NCI CTC
Grades 3–4) adverse events that were deemed related

or possibly related to the DCVax-L treatment. These
included cerebral edema in 3 patients (0.9%), seizures in
2 patients (0.6%), nausea in 1 patient (0.3%) and lymph
gland infection in 1 patient (0.3%).
The rate of total adverse events with SOC plus DCVaxL was comparable to SOC alone (Table 3). Non-serious
adverse events that were considered possibly related to
the treatment included injection site reactions, fatigue,
low-grade fever and night chills.

Discussion
Although enrollment was completed in 2015, this trial,
including both treatments and follow-up, is still ongoing
and will remain blinded until sufficient events of disease
progression and/or death have occurred to more fully
elucidate the tail of the survival curve. To date, due to
the crossover design, nearly 90% of the ITT population
received DCVax-L at some point in the trial, due to the
crossover design.
DCVax-L is administered by intra-dermal injection in
the arm, six times in year one and twice per year thereafter. It thereby imposes only a minimal burden on the
patient.
In the overall ITT population in this trial, the mOS of
23.1 months from surgery compares favorably with the
mOS of 15–17 months from surgery typically achieved
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Table 3 Grades 3–4 treatment-emergent adverse events
(TEAE)
System organ c lassa

Number (%)
of patients with TEAE
(n = 331)

Patients reporting at least one serious TEAE
(whether or not related to DC vaccine treat‑
ment)

137 (41.1%)

Nervous system disorders

93 (28.1%)

Infectionsb

23 (6.9%)

General disorders and injection site reactions

22 (6.6%)

Respiratory, thoracic and mediastinal disorders

17 (5.1%)

Psychiatric disorders

16 (4.8%)

Gastrointestinal disorders

16 (4.8%)

Injury, poisoning, and procedural complications

12 (3.6%)

Vascular disorders

6 (1.8%)

Musculoskeletal and connective tissue disor‑
ders

5 (1.5%)

Neoplasms benign, malignant and unspecified

5 (1.5%)

Hematological disorders

5 (1.5%)

Metabolism and nutrition disorders

3 (0.9%)

Hepatobiliary disorders

2 (0.6%)

Renal and urinary disorders

2 (0.6%)

Cardiac disorders

1 (0.3%)

Ear and labyrinth disorders

1 (0.3%)

Immune system disordersc

1 (0.3%)

Reproductive system and breast disorders

1 (0.3%)

a

Coded per MedDRA 16.0. Patients may have had more than one adverse event,
so subcategories do not total

b

Includes surgical wound infections, meningitis, urinary tract infections, and
others

c

Includes drug hypersensitivity

with SOC in past studies and clinical practice, as well as
with the survival data with SOC treatment in the control
arms of other trials in similar patient populations. For
example, Weller et al. reported mOS of 17.4 months from
randomization in the ITT population [21], and Stupp
et al. reported mOS of 16.0 months from randomization
in the ITT population [24].
In patients with a methylated MGMT gene promoter,
the mOS of 34.7 months from surgery also compares
favorably with SOC in past studies as well as with the
mOS reported for the control arm SOC treatments in
other recent glioblastoma trials in similar patient populations. For example, Stupp et al. reported for their control group an mOS of 21.2 months from randomization
in a similar patient population [24]. The increase in
survival in MGMT-methylated patients in the DCVaxL trial raises the possibility of a cooperative effect from
the combination of temozolomide chemotherapy and the
DCVax-L active immune therapy [17].
The mutation status of the IDH1 gene has not yet been
investigated for this trial, as this factor was not included

in trial designs a decade ago when this trial began. It will
be collected and analyzed later, but is unlikely to explain
the overall survival results, as the mutation associated
with prolonged survival occurs in less than 10% of newly
diagnosed glioblastoma patients [27].
Beneficial effects of immune therapies are often
observed at later time points, in the tail of the survival
curve [26]. Although this Phase 3 trial requires further maturation, a picture is beginning to emerge from
the blinded interim data which is consistent with an
extended survival tail. For example, among the patients
(n = 182) who were ≥ 36 months past their surgery date
as of the date of this analysis, 24.2% (n = 44) were alive
for ≥ 36 months and have a KM estimated median survival time of 88.2 months. Thus, it appears that patients
who survive past certain threshold time points may continue onwards to unusually long survival times, similar
to the findings in our prior Phase I/II studies of this DCbased vaccine [17–19]. Further maturation of the trial
data is needed to more fully reveal the extent of the long
tail of the survival curve.
DCVax-L has shown a benign safety profile in this
Phase 3 study, as it has consistently done in prior early
stage trials [17, 19], and in a large group of patients
treated on a compassionate use basis [28]. The fact that
only 7 of the 331 ITT patients (2.1%) experienced any
grade 3 or 4 adverse events that were at least possibly
related to the treatment makes this DC vaccine an especially well tolerated treatment.
With such a safety profile, this DC vaccine may be
administered in a wide range of clinical settings, and
can potentially be combined with a wide range of other
treatment agents, including immune checkpoint inhibitors and targeted therapies, without resulting in undue
toxicities for patients such as have been seen with some
other treatment combinations [29, 30]. Further studies to
explore such combinations are warranted.

Conclusions
The addition of DCVax-L autologous dendritic cell vaccine to SOC is feasible and safe. Collectively, the blinded
interim survival data suggest that the patients in this
Phase 3 trial are living longer than expected. These findings warrant further follow up and analyses.
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